BioMarin closes Alesta acquisition, but the filing adds little beyond confirmation

The filing confirms a transaction the market already knew was coming. BioMarin had previously disclosed the Share Purchase Agreement in its August 18, 2026 Form 8-K, so the August 31 closing is confirmation rather than a fresh strategic surprise.

The concrete change is ownership, not deal terms. The filing says Alesta Therapeutics is now fully owned by BioMarin following completion of the share purchase. 〔0〕

There is no clean earnings or valuation read in this filing. It provides no purchase price, revenue contribution, pipeline update, financing detail, or integration outlook, leaving the economic impact to be assessed from the earlier transaction disclosure and subsequent company reporting.

Net read: operationally meaningful, informationally neutral. Closing removes execution risk around the announced acquisition, but because the event was already disclosed and no new economics are provided, it does not establish a beat, miss, or incremental change versus expectations.